LGVN Q4 2023 Earnings — Longeveron Inc. Revenue & Financial Results | Market Cap Arena

LGVNLongeveron Inc.

$20M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$63,000-47.9% YoY

Gross Profit

-$2,000-3.2% margin

Operating Income

-$5M-8634.9% margin

Net Income

-$6M-9568.3% margin

EPS (Diluted)

$0.00

QoQ Revenue Growth

-58.0%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$413,000

Balance Sheet

Total Assets

$12M

Total Liabilities

$5M

Stockholders' Equity

$7M

Cash & Equivalents

$5M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$63,000	$121,000	-47.9%
Gross Profit	-$2,000	-$55,000	+96.4%
Operating Income	-$5M	-$5M	-3.8%
Net Income	-$6M	-$4M	-35.2%